Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Cites (292)

Items 201–285 of 285

1. Cdk12 is essential for embryonic development and the maintenance of genomic stability
   H. U. Juan, Yu-Ju Lin, H-R Chen, M-J Fann · 2015 · Cell Death and Differentiation
2. Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases
   Paul Andrew Clarke, Maria-Jesus Ortiz-Ruiz, Robert te Poele, Olajumoke Adeniji-Popoola, Gary Box, Will Court, Stephanie Czasch, Samer El Bawab, Christina Esdar, Kenneth Ewan et al. · 2016 · eLife
3. Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor–Positive Breast Cancer
   Hetal Patel, Rezvan Faisal Abduljabbar, Chun‐Fui Lai, Manikandan Periyasamy, Alison Harrod, Carolina Gemma, Jennifer H. Steel, Naina R. Patel, Claudia Busonero, Dena A. Jerjees et al. · 2016 · Clinical Cancer Research
4. The RNP protein, RNPS1, associates with specific isoforms of the P34CDC2 related PITSLRE protein kinase in vivo
   Pascal Loyer, Janeen H. Trembley, Jill M. Lahti, Vincent J. Kidd · 1998 · Journal of Cell Science
5. PITSLRE p110 Protein Kinases Associate with Transcription Complexes and Affect Their Activity
   Janeen H. Trembley, Dongli Hu, Li-Chung Hsu, C Y Yeung, Clive Arthur Slaughter, Jill M. Lahti, Vincent J. Kidd · 2002 · Journal of Biological Chemistry
6. Amplification of a 280-Kilobase Core Region at the ERBB2 Locus Leads to Activation of Two Hypothetical Proteins in Breast Cancer
   Päivikki Kauraniemi, Tuula Kuukasjärvi, Guido Sauter, Anne H. Kallioniemi · 2003 · American Journal Of Pathology
7. Genome-wide analysis of chromosomal alterations in patients with esophageal squamous cell carcinoma exposed to tobacco and betel quid from high-risk area in India
   Indranil Chattopadhyay, Avninder Singh, Rupkumar Phukan, Joydeep Purkayastha, Amal Chandra Kataki, Jagadish Mahanta, Sunita Saxena, Sujala Kapur · 2010 · Mutation Research/Genetic Toxicology and Environmental Mutagenesis
8. Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia
   Paolo Ghia, Lydia Scarfò, Susan Perez, Kumudu Pathiraja, Martha Derosier, Karen A. Small, Christine McCrary Sisk, Nigel W. Patton · 2017 · Blood
9. The p34 -related Cyclin-dependent kinase 11 Interacts with the p47 Subunit of Eukaryotic Initiation Factor 3 during Apoptosis
   Jiaqi Shi, Yongmei Feng, Anne‐Christine Goulet, Richard R. Vaillancourt, Nancy A. Sachs, John W.B. Hershey, Mark A. Nelson · 2003 · Journal of Biological Chemistry
10. A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility
    Wilson Kin Chung Leung, Arthur K.-K. Ching, Anthony W.H. Chan, Terence Chuen Wai Poon, H Mian, Alice S.T. Wong, Ka‐Fai To, N Wong · 2011 · Oncogene
11. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors
    Daruka Mahadevan, Ruth Plummer, Matthew S. Squires, Diane Rensvold, Sandra E Kurtin, Chris Pretzinger, Tomislav Dragovich, J. Adams, Victoria Lock, Donna-Michelle Smith et al. · 2011 · Annals of Oncology
12. Cdk11 is a RanGTP-dependent microtubule stabilization factor that regulates spindle assembly rate
    Hideki Yokoyama, Oliver J. Gruß, Sofia Rybina, Maïwen Caudron‐Herger, Malgorzata Schelder, Matthias S. Wilm, Iain W. Mattaj, Eric Karsenti · 2008 · The Journal of Cell Biology
13. Inability to enter S phase and defective RNA polymerase II CTD phosphorylation in mice lacking Mat1
    Derrick J. Rossi, Anou Londesborough, Nina Korsisaari, Arno Pihlak, Eero Lehtonen, Mark J. Henkemeyer, Tomi P. Mäkelä · 2001 · The EMBO Journal
14. CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome
    Vincent J. Guen, Carly Gamble, Marc Flajolet, Sheila Unger, Aurélie Thollet, Yoan Ferandin, Andrea Superti‐Furga, Pascale A. Cohen, Laurent Meijer, Pierre Colas · 2013 · Proceedings of the National Academy of Sciences
15. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
    Susan Burdette-Radoux, Richard G. Tozer, Reinhard C. Lohmann, Ian C. Quirt, D. Scott Ernst, Wendy Walsh, Nancy Wainman, Alexander Dimitrios Colevas, Elizabeth A. Eisenhauer · 2004 · Investigational New Drugs
16. A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine
    Elisabeth Jane Walsby, Guy Pratt, Hao Shao, Abdullah Y. Abbas, Peter M. Fischer, Tracey Dawn Bradshaw, Paul Brennan, Chris Fegan, Shudong Wang, Chris J. Pepper · 2013 · Oncotarget
17. Switching Cdk2 On or Off with Small Molecules to Reveal Requirements in Human Cell Proliferation
    Karl A. Merrick, Lara Wohlbold, Chao Zhang, Jasmina J. Allen, Dai Horiuchi, Noelle E. Huskey, Andrei Goga, Kevan M. Shokat, Robert P. Fisher · 2011 · Molecular Cell
18. Integrated Analysis of Whole Genome and Transcriptome Sequencing Reveals Diverse Transcriptomic Aberrations Driven by Somatic Genomic Changes in Liver Cancers
    Yuichi Shiraishi, Akihiro Fujimoto, Mayuko Furuta, Hiroko Tanaka, Kenichi Chiba, Keith A. Boroevich, Tetsuo Abe, Yoshiiku Kawakami, Masaki Ueno, Kunihito Gotoh et al. · 2014 · PLoS ONE
19. Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen
    Aurélie Mallinger, Simon Crumpler, Mark Pichowicz, Dennis Waalboer, Mark Stubbs, Olajumoke Adeniji-Popoola, Bozena Wood, Elizabeth L. Smith, Ching Thai, Alan T. Henley et al. · 2015 · Journal of Medicinal Chemistry
20. Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors
    Gábor Németh, Zoltán Greff, Anna Sipos, Zoltán Varga, Rita Székely, Mónika Sebestyén, Zsuzsa M. Jászay, Szabolcs Béni, Zoltán Nemes, Jean‐Luc Pirat et al. · 2014 · Journal of Medicinal Chemistry
21. Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells
    Michael F. T. Koehler, Philippe Bergeron, Elizabeth M. Blackwood, Krista K. Bowman, Kevin Clark, Ron Firestein, James R. Kiefer, K. Maskos, Mark L. McCleland, Linda Orren et al. · 2016 · ACS Medicinal Chemistry Letters
22. The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer
    Yubing Zhou, Jacson K. Shen, Francis John Hornicek, Quancheng Kan, Zhenfeng Duan · 2016 · Oncotarget
23. Cdk8 deletion in the ApcMin murine tumour model represses EZH2 activity and accelerates tumourigenesis
    Mark L. McCleland, Tim M. Soukup, Scot D. Liu, Jonathan H. Esensten, Felipe de Sousa e Melo, Murat Yaylaoglu, Søren Warming, Merone Roose‐Girma, Ron Firestein · 2015 · The Journal of Pathology
24. Cyclin-Dependent Kinase 7 Controls mRNA Synthesis by Affecting Stability of Preinitiation Complexes, Leading to Altered Gene Expression, Cell Cycle Progression, and Survival of Tumor Cells
    Timothy W. R. Kelso, Karen Baumgart, Jan Eickhoff, Thomas Albert, Claudia Antrecht, Sarah Lemcke, Bert Klebl, Michael Meisterernst · 2014 · Molecular and Cellular Biology
25. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
    Zhenghu Chen, Zhenyu Wang, Jonathan C. Pang, Yang Yu, Shayahati Bieerkehazhi, Jiaxiong Lu, Ting Hu, Yanling Zhao, Xin Yi Xu, Hong Zhang et al. · 2016 · Scientific Reports
26. The CTD code of RNA polymerase II: a structural view
    Olga Jasnovidova, Richard Štefl · 2012 · Wiley Interdisciplinary Reviews - RNA
27. Cell Cycle-dependent Regulation of the Forkhead Transcription Factor FOXK2 by CDK·Cyclin Complexes
    Anett Marais, Zongling Ji, Emma S. Child, Eberhard Krause, David J. Mann, Andrew D Sharrocks · 2010 · Journal of Biological Chemistry
28. CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
    Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna L. Riffell, Alberto Bardelli, Christopher J. Torrance, Christopher J. Lord et al. · 2016 · PLoS ONE
29. CDK8 kinase—An emerging target in targeted cancer therapy
    Tomasz Rzymski, Michał Mikuła, Katarzyna Wiklik, Krzysztof D. Brzózka · 2015 · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
30. CDK8 regulates E2F1 transcriptional activity through S375 phosphorylation
    Jia Zhao, Robert Ramos, Mark J. Demma · 2012 · Oncogene
31. The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer
    Anirban Pradip Mitra, Arpit A. Almal, Ben George, David W. Fry, Peter F. Lenehan, Vincenzo Pagliarulo, Richard J. Côté, Ram H. Datar, William P. Worzel · 2006 · BMC Cancer
32. Cyclin-dependent kinase 11p110 (CDK11p110) is crucial for human breast cancer cell proliferation and growth
    Yubing Zhou, Chao Han, Duolu Li, Zujiang Yu, Fengmei Li, Feng Li, Qi An, Huili Bai, Xiaojian Zhang, Zhenfeng Duan et al. · 2015 · Scientific Reports
33. A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177
    E X Chen, Sebastién J. Hotte, Hal W. Hirte, Lillian L. Siu, J Lyons, Matthew S. Squires, Sonya Lovell, S Turner, L McIntosh, Lesley Seymour · 2014 · British Journal of Cancer
34. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy
    Betsy T. Kren, Gretchen M. Unger, Md. Joynal Abedin, Rachel Isaksson Vogel, Christine M. Henzler, Khalil Ahmed, Janeen H. Trembley · 2015 · Breast Cancer Research
35. Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation
    Zhenfeng Duan, Jianming Zhang, Edwin Choy, David C. Harmon, Xianzhe Liu, Petur Nielsen, Henry J. Mankin, Nathanael S. Gray, Francis John Hornicek · 2012 · Clinical Cancer Research
36. A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer
    Glenn Liu, David R. Gandara, Primo N. Lara, Derek Raghavan, James H. Doroshow, Przemyslaw W. Twardowski, Philip W. Kantoff, William K. Oh, KyungMann Kim, George Wilding · 2004 · Clinical Cancer Research
37. Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy
    Clara Albanese, Rachele Alzani, Nadia Amboldi, Nilla Roberta Avanzi, Dario Ballinari, Maria Gabriella Brasca, Claudio Festuccia, Francesco Fiorentini, Giuseppe Locatelli, Wilma Pastori et al. · 2010 · Molecular Cancer Therapeutics
38. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
    M. Emmy M. Dolman, Evon Poon, Marli E. Ebus, Ilona J.M. den Hartog, Carel J.M. van Noesel, Yann Jamin, Albert Hallsworth, Simon P. Robinson, Kevin R. Petrie, Rolf W. Sparidans et al. · 2015 · Clinical Cancer Research
39. Cross-talk Among RNA Polymerase II Kinases Modulates C-terminal Domain Phosphorylation
    Ballachanda N. Devaiah, Dinah S. Singer · 2012 · Journal of Biological Chemistry
40. Cyclin-Dependent Kinase 12 Increases 3′ End Processing of Growth Factor-Induced c-FOS Transcripts
    Tristan Eifler, Wei Shao, Koen Bartholomeeusen, Koh Fujinaga, Stefanie Jäger, Jeffrey R. Johnson, Zeping Luo, Nevan J. Krogan, Boris Matija Peterlin · 2014 · Molecular and Cellular Biology
41. CDKI‐71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol
    Xiangrui Liu, Shenhua Shi, Frankie Lam, Chris J. Pepper, Peter M. Fischer, Shudong Wang · 2011 · International Journal of Cancer
42. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
    David S. Boss, Gary K. Schwartz, Mark Ross Middleton, Dereck Dokyi Amakye, Helen Swaisland, Rachel S. Midgley, Malcolm Ranson, Sarah J. Danson, Hilary Calvert, Ruth Plummer et al. · 2009 · Annals of Oncology
43. Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8
    Philippe Bergeron, Michael F. T. Koehler, Elizabeth M. Blackwood, Krista K. Bowman, Kevin Clark, Ron Firestein, James R. Kiefer, K. Maskos, Mark L. McCleland, Linda Orren et al. · 2016 · ACS Medicinal Chemistry Letters
44. Phosphorylation of RNAPII
    Bartlomiej Bartkowiak, Arno L. Greenleaf · 2011 · Transcription
45. The Cyclin-Dependent Kinase Inhibitor Seliciclib (R-roscovitine; CYC202) Decreases the Expression of Mitotic Control Genes and Prevents Entry into Mitosis
    Steven R. Whittaker, Robert te Poele, Florence Chan, Spiros Linardopoulos, Michael I. Walton, Michelle Dawn Garrett, Paul Workman · 2007 · Cell Cycle
46. Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells
    Bin Jia, Edwin Choy, Gregory Michael Cote, David C. Harmon, Shunan Ye, Quancheng Kan, Henry J. Mankin, Francis John Hornicek, Zhenfeng Duan · 2013 · Cancer Letters
47. AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples
    Matthew S. Squires, Laurence S. Cooke, Victoria Lock, Wenqing Qi, Edward J. Lewis, Neil T. Thompson, John F. Lyons, Daruka Mahadevan · 2010 · Molecular Cancer Therapeutics
48. Cyclin Dependent Kinase 11 in RNA Transcription and Splicing
    Janeen H. Trembley, Pascal Loyer, Dongli Hu, Tongyuan Li, Jose A. Grenet, Jill M. Lahti, Vincent J. Kidd · 2004 · Progress in nucleic acid research and molecular biology
49. Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73
    Frankie Lam, Abdullahi Yahya Abbas, Hao Shao, Theodosia Teo, Julian Adams, Peng Li, Tracey Dawn Bradshaw, Peter M. Fischer, Elisabeth Jane Walsby, Chris J. Pepper et al. · 2014 · Oncotarget
50. Expression, Purification, and Identification of Associated Proteins of the Full-length hCDK12/CyclinK Complex
    Bartlomiej Bartkowiak, Arno L. Greenleaf · 2014 · Journal of Biological Chemistry
51. Mitosis-Specific Phosphorylation of Nucleolin by p34 cdc2 Protein Kinase
    Pascale Belenguer, Michèle Caizergues‐Ferrer, Jean‐Claude Labbé, Marcel Dorée, François Amalric · 1990 · Molecular and Cellular Biology
52. Roles of cyclin-dependent kinase 8 and β-catenin in the oncogenesis and progression of gastric adenocarcinoma
    Lim · 2011 · International Journal of Oncology
53. Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)
    Richard S. Finn, John Paul Crown, István Láng, Katalin Boér, Igor M. Bondarenko, Sergey O. Kulyk, Johannes Ettl, Ravindranath Patel, Tamás Pintér, Marcus Schmidt et al. · 2014 · Cancer Research
54. Selective control of gene expression by CDK9 in human cells
    Judit Garriga, Hongbo Michael Xie, Zoran Obradovic A, Xavier Graña · 2009 · Journal of Cellular Physiology
55. PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma
    Tingting Sun, Ngai Na Co, Nathalie Wong · 2014 · Biochemical and Biophysical Research Communications
56. Systematic Determination of Human Cyclin Dependent Kinase (CDK)-9 Interactome Identifies Novel Functions in RNA Splicing Mediated by the DEAD Box (DDX)-5/17 RNA Helicases*
    Jun Yang, Yingxin Zhao, Mridul Kumar Kalita, Xueling Li, Mohammad Jamaluddin, Bing Tian, Chukwudi B. Edeh, John E. Wiktorowicz, Andrzej S. Kudlicki, Allan R. Brasier · 2015 · Molecular & Cellular Proteomics
57. Engineering an analog-sensitive CDK12 cell line using CRISPR/Cas
    Bartlomiej Bartkowiak, Christopher M. Yan, Arno L. Greenleaf · 2015 · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
58. Tumor-suppressive effects of CDK8 in endometrial cancer cells
    Weiting Gu, Chenguang Wang, Weihua Li, Fu-Ning Hsu, Lifeng Tian, Jie Zhou, Cunzhong Yuan, Xiao-Jun Xie, Tao Jiang, Sankar Addya et al. · 2013 · Cell Cycle
59. PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration and Invasion
    Lei Yang, Jia Yun Zhu, Hua Huang, Qichang Yang, Jing Cai, Qiuhong Wang, Junya Zhu, Mengting Shao, Jinzhang Xiao, Jie Cao et al. · 2015 · PLoS ONE
60. 2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19
    Aurélie Mallinger, Kai Schiemann, Christian Rink, Jimmy J. P. Sejberg, Mark A. Honey, Paul Czodrowski, Mark Stubbs, Oliver Poeschke, Michael Busch, Richard Schneider et al. · 2016 · ACS Medicinal Chemistry Letters
61. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
    Emiliano Cocco, Salvatore Lopez, Jonathan Black, Stefania Bellone, Elena Bonazzoli, Federica Predolini, Francesca Ferrari, Carlton L. Schwab, Gulden Menderes, Luca Arrigo Zammataro et al. · 2016 · British Journal of Cancer
62. Role of CDK8 and β-catenin in colorectal adenocarcinoma
    Lim · 2010 · Oncology Reports
63. Cdk9 T‐loop phosphorylation is regulated by the calcium signaling pathway
    Rajesh Ramakrishnan, Andrew P. Rice · 2011 · Journal of Cellular Physiology
64. Zooming in on Transcription Preinitiation
    Kapil Gupta, Duygu Sari, Matthias Haffke, Simon Trowitzsch, Imre Berger · 2016 · Journal of Molecular Biology
65. LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer
    Patnaik, Amita, Rosen, Lee S., Tolaney, Sara M., Tolcher, Anthony W., Goldman, Jonathan Wade, Gandhi, Leena, Papadopoulos, Kyriakos P., Beeram, Muralidhar, Rasco, Drew Warren, Myrand, Scott P. et al. · 2014 · Journal of Clinical Oncology
66. Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies
    Glen J. Weiss, Manuel M. Hidalgo, Mitesh J. Borad, Daniel A. Laheru, Raoul Tibes, Ramesh K. Ramanathan, Lisa Blaydorn, Gayle Jameson, Antonio Jimeno, Jeffrey D. Isaacs et al. · 2011 · Investigational New Drugs
67. Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore
    Kai Schiemann, Aurélie Mallinger, Dirk Wienke, Christina Esdar, Oliver Poeschke, Michael Busch, Felix Rohdich, Suzanne A. Eccles, Richard Schneider, Florence I. Raynaud et al. · 2016 · Bioorganic & Medicinal Chemistry Letters
68. CDK11p58 Is Required for Centriole Duplication and Plk4 Recruitment to Mitotic Centrosomes
    Nathalie Franck, Émilie Montembault, Pierre Romé, Aude Pascal, Jean-Yves Crémet, Régis Giet · 2011 · PLoS ONE
69. The cyclin-dependent kinase 11p46 isoform interacts with RanBPM
    Monika Mikołajczyk, Jiaqi Shi, Richard R. Vaillancourt, Nancy A. Sachs, Mark A. Nelson · 2003 · Biochemical and Biophysical Research Communications
70. Human mediator kinase subunit CDK11 plays a negative role in viral activator VP16‐dependent transcriptional regulation
    Taiki Tsutsui, Hiroyasu Umemura, Aki Tanaka, F. Mizuki, Yutaka Hirose, Y. Ohkuma · 2008 · Genes to Cells
71. The impact of CDK9 on radiosensitivity, DNA damage repair and cell cycling of HNSCC cancer cells
    Katja Storch, Nils Cordes · 2015 · International Journal of Oncology
72. PCTAIRE1/PCTK1/CDK16: a new oncotarget?
    Teruki Yanagi, Shu‐ichi Matsuzawa · 2015 · Cell Cycle
73. Gene‐specific requirement of RNA polymerase II CTD phosphorylation
    Julie Drogat, Damien Hermand · 2012 · Molecular Microbiology
74. Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors
    Stuart C. Wilson, Butrus Atrash, Clare Barlow, Susan Eccles, Peter M. Fischer, Angela Hayes, Lloyd R. Kèlland, Wayne Jackson, Michael Jarman, Amin R. Mirza et al. · 2011 · Bioorganic & Medicinal Chemistry
75. A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs)
    S. Diab, S. Gail Eckhardt, Antoinette R. Tan, Gary Frenette, Lia Gore, Wanda DePinto, Joseph F. Grippo, Mark DeMario, Stanislaw M. Mikulski, S. Papadimitrakopoulou · 2007 · Journal of Clinical Oncology
76. Identification of murine cdk10: Association with Ets2 transcription factor and effects on the cell cycle
    Luigi Bagella, Cristina Giacinti, Cristiano Simone, Antonio Giordano · 2006 · Journal of Cellular Biochemistry
77. CDK11p58 kinase activity is required to protect sister chromatid cohesion at centromeres in mitosis
    Tarik Rakkaa, Christophe Escudé, Régis Giet, Laura Magnaghi-Jaulin, Christian Jaulin · 2014 · Chromosome Research
78. CRK7 modifies the MAPK pathway and influences the response to endocrine therapy
    Elizabeth J. Iorns, Sanne R. Martens‐de Kemp, Christopher J. Lord, Alan Ashworth · 2009 · Carcinogenesis
79. A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma
    Winnie Yeo, Boon Cher Goh, Christophe Le Tourneau, S.R. Green, Judy H. Chiao, Lillian L. Siu · 2009 · Journal of Clinical Oncology
80. A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib Compared to Ofatumumab in Patients with Refractory Chronic Lymphocytic Leukemia
    Paolo Ghia, Lydia Scarfò, Kumudu Pathiraja, Martha Derosier, Karen A. Small, Nigel W. Patton · 2015 · Blood
81. Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.
    Sara M. Tolaney, John Frederick Hilton, James M. Cleary, Leena Gandhi, Eunice Lee Kwak, Jeffrey William Clark, Andrew Wolanski, Tracy Demeo Bell, Scott J. Rodig, Judy H. Chiao et al. · 2016 · Journal of Clinical Oncology
82. Inhibition of P-TEFb by DRB suppresses SIRT1/CK2α pathway and enhances radiosensitivity of human cancer cells.
    Zhi-Qiang Wang, Casey L Johnson, Amit Kumar, David P. Molkentine, Jessica M. Molkentine, Tatiana Rabin, Kathryn A. Mason, Luka Milas, Uma Raju · 2014 · PubMed
83. CYC065, potential therapeutic agent for AML and MLL leukaemia
    Sheelagh Frame, Chiara Saladino, Susan Davis, David Blake, Daniella I. Zheleva · 2015 · Clinical Lymphoma Myeloma & Leukemia
84. A first-in-human phase I study of oral pan-CDK inhibitor BAY 1000394 in patients with advanced solid tumors: Dose escalation with an intermittent 3 days on/4 days off schedule.
    Rastislav Bahleda, Anas Gazzah, Andréa Varga, Prabhu Rajagopalan, David Andrew Henderson, Martin Kornacker, Jean‐Charles Soria · 2012 · Journal of Clinical Oncology
85. Abstract 562: Dinaciclib induces immunogenic cell death and enhances anti-PD-1 mediated tumor suppression
    Dewan Hossain, Fernando Ugarte, Anandi Sawant, Mingmei Cai, Venkataraman Sriram, Elaine M. Pinheiro, Svetlana Sadekova, Alissa A. Chackerian · 2016 · Cancer Research